Cargando…
Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease
Although interstitial lung disease (ILD) is a life-threatening pathological condition that causes respiratory failure, the efficiency of current therapies is limited. This study aimed to investigate the effects of human MIKO-1 (hMIKO-1), a hybrid protein that suppresses the abnormal activation of ma...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456133/ https://www.ncbi.nlm.nih.gov/pubmed/36077067 http://dx.doi.org/10.3390/ijms23179669 |
_version_ | 1784785737622749184 |
---|---|
author | Kotani, Takuya Ikemoto, Masaki Matsuda, Shogo Masutani, Ryota Takeuchi, Tohru |
author_facet | Kotani, Takuya Ikemoto, Masaki Matsuda, Shogo Masutani, Ryota Takeuchi, Tohru |
author_sort | Kotani, Takuya |
collection | PubMed |
description | Although interstitial lung disease (ILD) is a life-threatening pathological condition that causes respiratory failure, the efficiency of current therapies is limited. This study aimed to investigate the effects of human MIKO-1 (hMIKO-1), a hybrid protein that suppresses the abnormal activation of macrophages, on murine macrophage function and its therapeutic effect in a mouse model of bleomycin-induced ILD (BLM-ILD). To this end, the phenotype of thioglycolate-induced murine peritoneal macrophages co-cultured with hMIKO-1 was examined. The mice were assigned to normal, BLM-alone, or BLM + hMIKO-1 groups, and hMIKO-1 (0.1 mg/mouse) was administered intraperitoneally from day 0 to 14. The mice were sacrificed on day 28, and their lungs were evaluated by histological examination, collagen content, and gene expression levels. hMIKO-1 suppressed the polarization of murine macrophages to M2 predominance in vitro. The fibrosis score of lung pathology and lung collagen content of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. The expression levels of TNF-α, IL-6, IL-1β, F4/80, and TIMP-1 in the lungs of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. These findings indicate that hMIKO-1 reduces lung fibrosis and may be a future therapeutic candidate for ILD treatment. |
format | Online Article Text |
id | pubmed-9456133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94561332022-09-09 Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease Kotani, Takuya Ikemoto, Masaki Matsuda, Shogo Masutani, Ryota Takeuchi, Tohru Int J Mol Sci Article Although interstitial lung disease (ILD) is a life-threatening pathological condition that causes respiratory failure, the efficiency of current therapies is limited. This study aimed to investigate the effects of human MIKO-1 (hMIKO-1), a hybrid protein that suppresses the abnormal activation of macrophages, on murine macrophage function and its therapeutic effect in a mouse model of bleomycin-induced ILD (BLM-ILD). To this end, the phenotype of thioglycolate-induced murine peritoneal macrophages co-cultured with hMIKO-1 was examined. The mice were assigned to normal, BLM-alone, or BLM + hMIKO-1 groups, and hMIKO-1 (0.1 mg/mouse) was administered intraperitoneally from day 0 to 14. The mice were sacrificed on day 28, and their lungs were evaluated by histological examination, collagen content, and gene expression levels. hMIKO-1 suppressed the polarization of murine macrophages to M2 predominance in vitro. The fibrosis score of lung pathology and lung collagen content of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. The expression levels of TNF-α, IL-6, IL-1β, F4/80, and TIMP-1 in the lungs of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. These findings indicate that hMIKO-1 reduces lung fibrosis and may be a future therapeutic candidate for ILD treatment. MDPI 2022-08-26 /pmc/articles/PMC9456133/ /pubmed/36077067 http://dx.doi.org/10.3390/ijms23179669 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kotani, Takuya Ikemoto, Masaki Matsuda, Shogo Masutani, Ryota Takeuchi, Tohru Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease |
title | Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease |
title_full | Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease |
title_fullStr | Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease |
title_full_unstemmed | Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease |
title_short | Human MIKO-1, a Hybrid Protein That Regulates Macrophage Function, Suppresses Lung Fibrosis in a Mouse Model of Bleomycin-Induced Interstitial Lung Disease |
title_sort | human miko-1, a hybrid protein that regulates macrophage function, suppresses lung fibrosis in a mouse model of bleomycin-induced interstitial lung disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456133/ https://www.ncbi.nlm.nih.gov/pubmed/36077067 http://dx.doi.org/10.3390/ijms23179669 |
work_keys_str_mv | AT kotanitakuya humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease AT ikemotomasaki humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease AT matsudashogo humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease AT masutaniryota humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease AT takeuchitohru humanmiko1ahybridproteinthatregulatesmacrophagefunctionsuppresseslungfibrosisinamousemodelofbleomycininducedinterstitiallungdisease |